
|Articles|September 1, 2007
- Volume 0 0
can you READ these Rxs?
Advertisement
Amy Gayer, senior pharmacy technician, ofWalgreens #5553 in Hoffman Estates, Ill, knewthat this prescription was going to be a problemwhen it was brought into the pharmacy. Sheasked several staff members whether theywere able to decipher what medicine thephysician was ordering. When she had nosuccess, she called the physician?s officefor assistance. Can you solve this mysteryprescription?
Click Here For The Answer ----------->
[
Nicotrol inhaler, #1 inhaler, take as directed.
toggle(getObject('exp1048685570_link'), 'exp1048685570');
Articles in this issue
about 19 years ago
Calming the Symptoms of Menopauseabout 19 years ago
Zoster Vaccineabout 19 years ago
pharmacy TECHNOLOGY productsabout 19 years ago
health-systems PRODUCT newsabout 19 years ago
can you READ these Rxs?about 19 years ago
Generic Times Product Newsabout 19 years ago
compounding HOTLINEabout 19 years ago
Human HRT Leads Compounding Renaissanceabout 19 years ago
Prescription-overdose Deaths Surpass Car-accident Deathsabout 19 years ago
43 Years Later, a DES Case Is Still in the Court SystemAdvertisement
Related to this article

Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.

A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.

Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.

The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5



